Transfusion/Hemostasis clinical research network

描述(由申请人提供) 这是宾夕法尼亚大学医学院继续参与输血医学/止血临床试验网络的申请。该小组包括宾夕法尼亚大学卫生系统、费城儿童医院(CHOP)和美国红十字会宾夕法尼亚-泽西分会(PJ-ARC)的资源，并包括儿童和成人止血和输血医学方面的专业知识。我们的网站在CTN中非常活跃，包括参加常设委员会和小组委员会，包括担任小组委员会主席和为CTN撰写的手稿做出贡献。我们一直积极参与研究开发，并正在招募患者参加两项活跃的网络研究(PLADO和SHIP)，并计划参与接近登记的研究。康克尔博士将于2006年9月开始担任CTN主席，共同调查者拉菲尼博士和瓦萨洛博士目前分别担任遗传性出血疾病和血小板小组委员会的联合主席。我们计划在未来5年继续积极参与CTN，以实现以下具体目标：1)维持并根据需要进一步加强结构，以支持输血医学和止血领域的临床试验的开发、实施和进行。这将与NERI作为数据协调中心和NHLBI的项目工作人员合作完成。2)利用工作和研究监督小组委员会的这种结构，完成正在进行的试验，并开发、完善和完成本申请中提议的新试验。3)发展合作关系和支持培训机会，以促进拟议的临床试验的成功，并促进输血医学和止血领域的进一步发展。4)通过介绍和出版临床试验结果和其他TMH CTN活动来传播TMH CTN的成果。TMH CTN的临床研究结果将极大地加强对止血障碍患者和许多接受输血患者的护理。我们期待着继续在这些努力中工作。 全面的网络批评

DESCRIPTION (provided by applicant) This is an application from the University of Pennsylvania School of Medicine for continued participation in the Transfusion Medicine/Hemostasis Clinical Trial Network. This group includes the resources of the University of Pennsylvania Health System, the Children's Hospital of Philadelphia (CHOP) and the Penn- Jersey Division of the American Red Cross (PJ-ARC), and includes expertise in pediatric and adult hemostasis and transfusion medicine. Our site has been very active in the CTN including participating in standing committees and subcommittees, including being subcommittee chairs and contributing to CTN authored manuscripts. We have been actively involved in study development and are enrolling patients in the two active network studies (PLADO and SHIP), with plans for participation in the studies nearing enrollment. Dr. Konkle, P.I., will begin as Chair of the CTN in September 2006 and co-investigators Dr. Raffini and Vassallo, currently serve as co-chairs of the Inherited Bleeding Disorder and Platelet subcommittees, respectively. We plan to continue our active involvement in the CTN for the next 5 years, to achieve the Specific Aims to: 1) Maintain, and further enhance, as needed, a structure to support the development, implementation and conduct of clinical trials in the areas of transfusion medicine and hemostasis. This will be done in collaboration with the NERI as Data Coordinating Center, and program staff at NHLBI. 2) Utilizing this structure of working and study oversight subcommittees, complete ongoing trials and develop, refine and complete new trials proposed in this application. 3) Develop collaborative relationships and support training opportunities to facilitate the success of the proposed clinical trials and further the fields of transfusion medicine and hemostasis. 4) Disseminate results of the TMH CTN through presentations and publications of clinical trial results and other TMH CTN activities. The results of the clinical studies performed by the TMH CTN will greatly enhance the care of patients with disorders of hemostasis and the many patients receiving blood transfusions. We look forward to continuing to work in these efforts. OVERALL NETWORK CRITIQUES